Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $44.7 million.

  • Enanta Pharmaceuticals' Total Current Liabilities fell 881.14% to $44.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $44.7 million, marking a year-over-year decrease of 881.14%. This contributed to the annual value of $48.6 million for FY2025, which is 1560.79% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Total Current Liabilities stood at $44.7 million for Q4 2025, which was down 881.14% from $48.6 million recorded in Q3 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Total Current Liabilities ranged from a high of $68.2 million in Q2 2023 and a low of $23.0 million during Q4 2022
  • In the last 5 years, Enanta Pharmaceuticals' Total Current Liabilities had a median value of $44.6 million in 2025 and averaged $43.2 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Total Current Liabilities plummeted by 3929.53% in 2022, and later soared by 19602.34% in 2023.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Total Current Liabilities stood at $37.9 million in 2021, then tumbled by 39.3% to $23.0 million in 2022, then surged by 171.32% to $62.4 million in 2023, then decreased by 21.4% to $49.0 million in 2024, then decreased by 8.81% to $44.7 million in 2025.
  • Its Total Current Liabilities was $44.7 million in Q4 2025, compared to $48.6 million in Q3 2025 and $44.5 million in Q2 2025.